Title

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Authoring Organization

Publication Month/Year

November 1, 2021

Last Updated Month/Year

November 7, 2024

Supplemental Implementation Tools

• Patient Information
• Slide Set
• Slide Set
• Quick-Reference Guide
• Patient Information
• Patient Information
• Quick-Reference Guide
• Visual Abstract
• Quick-Reference Guide
• Podcast

Document Type

Guideline

External Publication Status

Published

Country of Publication

US

Document Objectives

To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy.

Target Patient Population

Adult patients with cancer receiving treatment with immune checkpoint blockade inhibitors alone

Target Provider Population

Health care practitioners, including oncologists, other medical subspecialists, emergency medicine, internal and family medicine practitioners, nurses, and pharmacists

PICO Questions

1. How should clinicians manage immune-mediated adverse events (AEs) in adult patients with cancer treated with immune checkpoint blockade antibodies?

2. In addition, the guideline addresses how AEs related to steroid use can be prevented and managed.

Inclusion Criteria

Male, Female, Adolescent, Adult, Child, Older adult

Health Care Settings

Ambulatory, Emergency care, Hospital, Outpatient

Intended Users

Healthcare business administration, nurse, nurse practitioner, community pharmacist, health systems pharmacist, physician, physician assistant

Scope

Management, Prevention

Diseases/Conditions (MeSH)

D007167 - Immunotherapy, D064420 - Drug-Related Side Effects and Adverse Reactions, D000082082 - Immune Checkpoint Inhibitors

Keywords

immune checkpoint inhibitor (ICI), Immune Checkpoint Inhibitor, Immune-Related Adverse Events, IRAEs, Cancer immunotherapy, Keytruda, Opdivo, ICPis

Source Citation

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36): 4073-4126. doi: 10.1200/JCO.21.0.1440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. PM ID: 34724392

Supplemental Methodology Resources

Data Supplement